Amphastar Pharma (AMPH) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Amphastar Pharmaceuticals Reports Revenues of $55.9 Million for the Fourth Quarter Ended December 31, 2014
March 24, 2015 4:01 PM EDTRANCHO CUCAMONGA, Calif., March 24, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq: AMPH) ("Amphastar" or the "Company") today reported results for the fourth quarter ended December 31, 2014.
Net revenues of $55.9 million for the fourth quarter GAAP net loss of $2.5 million, or $0.06 per diluted share for the fourth quarter Adjusted non-GAAP net loss of $1.5 million, or $0.03 per diluted share for the fourth quarter  Three Months Ended December 31, Years Ended December 31,  2014 2013 2014 2013  (in thousands, except per share data) Net revenues... More